Plain-English translation of NCT05835518 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →This is an observational study that follows patients taking Adalloce, a medication prescribed to treat rheumatoid arthritis or ankylosing spondylitis. Researchers will track how well the medication works for you and any side effects you experience over time. The study is designed to gather real-world information about how this treatment performs in everyday clinical practice.
While this medication has been developed and approved, doctors want to learn more about how it actually works in a broad range of patients in real-world settings. This study will help answer questions about the medication's long-term effectiveness and safety profile.
You likely qualify if…
You likely don't qualify if…
Since this is an observational study, you will continue taking the medication as your doctor normally prescribes it—you are not being asked to do anything different from standard care. Researchers will monitor your health and symptoms over time, likely through clinic visits and medical records, to see how you respond to the treatment and track any side effects. The study aims to enroll around 1,000 patients to build a complete picture of how the medication works in everyday practice.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
South Korea
Sponsor
Yuhan Corporation
Enrollment target
~1,000 participants
Started
January 2023
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
19 Years – 74 Years
Last updated on clinicaltrials.gov in May 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hee Suh
Daegu Catholic University Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.